This week in drug discovery (22-26 July)
News round-up for 22-26 July by DDW Senior Digital Content Editor Diana Spencer.
There have been some interesting developments in neuroscience this week. Perhaps most note-worthy, shingles vaccines Shingrix has been shown to reduce the risk of dementia by 17%, and TikoMed’s ALS drug caused a long-term slowing of ALS progression in a Phase II trial.
The top stories:
Oxford centre to address global epilepsy challenges
The University of Oxford is launching The Centre for Global Epilepsy to address the global burden of epilepsy, particularly in lower-income countries.
‘Encouraging’ results for potential disease-modifying ALS drug
New clinical data have shown that TikoMed’s low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS).
Lario Therapeutics awarded $6m for Parkinson’s drug research
Biopharmaceutical company Lario Therapeutics has been awarded a $6 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
SynaptixBio and Evotec extend rare disease therapies partnership
SynaptixBio and Evotec have announced they are extending their partnership to find further candidate drugs to treat H-ABC, the most severe form of TUBB4A leukodystrophy.
New shingles vaccine found to reduce risk of dementia
New evidence indicates that a new shingles vaccine is more protective against dementia compared to the previous shingles vaccine, which was also reported to reduce dementia rates.
